Remd Biotherapeutics Inc., of Camarillo, Calif., and subsidiary Beijing Cosco-Remd Bio Med-Tech Co. Ltd., said the first patient with type 1 diabetes was dosed with REMD-477 in a randomized, double-blind, placebo-controlled phase Ib trial designed to evaluate safety, tolerability, pharmacodynamics, and glucose and insulin dose-lowering properties of the antibody drug, which is designed to block the glucagon receptor. Up to 20 patients will be enrolled and will receive a single subcutaneous injection.